Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
type: MedicalStudy
description: Mitigating Anthracycline-Induced Cardiac Toxicity With Dapagliflozin: A Randomized, Double-Blind, Placebo-Controlled Trial of 10 mg Daily for Four Months
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2024-09-01
end date: 2025-09-06
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT06888505
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Hawler Medical University
study subject: Anthracyclines-Induced Cardiotoxicity
study subject: Cardiotoxicity
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Anthracyclines-Induced Cardiotoxicity
keywords: Cardiotoxicity

AI Analytics
type: Organization